Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
Pratheesh Sathyan,Pascal O Zinn,Anantha L Marisetty,Bin Liu,Mohamed Mostafa Kamal,Sanjay K Singh,Pierre Bady,Li Lu,Khalida M Wani,Bethany L Veo,Joy Gumin,Dina Hamada Kassem,Frederick Robinson,Connie Weng,Veerabhadran Baladandayuthapani,Dima Suki,Howard Colman,Krishna P Bhat,Erik P Sulman,kenneth d aldape,Rivka R Colen,Roel G W Verhaak,Zhimin Lu,Gregory N Fuller,Suyun Huang,Frederick F Lang,Raymond Sawaya,monika e hegi,Sadhan Majumder
DOI: https://doi.org/10.1523/JNEUROSCI.1265-15.2015
2015-01-01
Journal of Neuroscience
Abstract:Glioblastoma (GBM) is the most aggressive human brain tumor. Although several molecular subtypes of GBM are recognized, a robust molecular prognostic marker has yet to be identified. Here, we report that the stemness regulator Sox2 is a new, clinically important target of microRNA-21 (miR-21) in GBM, with implications for prognosis. Using the MiR-21-Sox2 regulatory axis, approximately half of all GBM tumors present in the Cancer Genome Atlas (TCGA) and in-house patient databases can be mathematically classified into high miR-21/low Sox2 (Class A) or low miR-21/high Sox2 (Class B) subtypes. This classification reflects phenotypically and molecularly distinct characteristics and is not captured by existing classifications. Supporting the distinct nature of the subtypes, gene set enrichment analysis of the TCGA dataset predicted that Class A and Class B tumors were significantly involved in immune/inflammatory response and in chromosome organization and nervous system development, respectively. Patients with Class B tumors had longer overall survival than those with Class A tumors. Analysis of both databases indicated that the Class A/Class B classification is a better predictor of patient survival than currently used parameters. Further, manipulation of MiR-21-Sox2 levels in orthotopic mouse models supported the longer survival of the Class B subtype. The MiR-21-Sox2 association was also found in mouse neural stem cells and in the mouse brain at different developmental stages, suggesting a role in normal development. Therefore, this mechanism-based classification suggests the presence of two distinct populations of GBM patients with distinguishable phenotypic characteristics and clinical outcomes.